At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 167 enrolled
Drug / intervention
Matching Placebo +1 moredrug
Likely dose
Verdiperstat 600mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HEALEY ALS Platform Trial - Regimen B Verdiperstat
In Brief
A Phase 3 clinical trial evaluating Matching Placebo and Verdiperstat for Amyotrophic Lateral Sclerosis. Completed, enrolled 167 participants across 1 site.
Detailed Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen B will evaluate the safety and efficacy of a single study drug, verdiperstat, in participants with ALS.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyotrophic Lateral Sclerosis
CountriesUnited States
CollaboratorsBiohaven Pharmaceuticals, Inc.
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionApr 2022
Study CompletionDec 2022
TodayJul 2026
First PostedJun 18, 2020
Enrollment StartJul 28, 2020
Primary CompletionApr 13, 2022
Study CompletionDec 6, 2022
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.0 years ago
Interventions
Matching Placebodrug
Drug: Matching Placebo Administration: Oral Dose: two tablets twice daily
Verdiperstatdrug
Drug: Verdiperstat Administration: Oral Dose: 600mg twice daily